These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 22491949)

  • 1. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
    Hrkach J; Von Hoff D; Mukkaram Ali M; Andrianova E; Auer J; Campbell T; De Witt D; Figa M; Figueiredo M; Horhota A; Low S; McDonnell K; Peeke E; Retnarajan B; Sabnis A; Schnipper E; Song JJ; Song YH; Summa J; Tompsett D; Troiano G; Van Geen Hoven T; Wright J; LoRusso P; Kantoff PW; Bander NH; Sweeney C; Farokhzad OC; Langer R; Zale S
    Sci Transl Med; 2012 Apr; 4(128):128ra39. PubMed ID: 22491949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy.
    Werner ME; Copp JA; Karve S; Cummings ND; Sukumar R; Li C; Napier ME; Chen RC; Cox AD; Wang AZ
    ACS Nano; 2011 Nov; 5(11):8990-8. PubMed ID: 22011071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
    Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
    J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles.
    Au KM; Min Y; Tian X; Zhang L; Perello V; Caster JM; Wang AZ
    ACS Nano; 2015 Sep; 9(9):8976-96. PubMed ID: 26267360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
    Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
    J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
    Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
    Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
    Farokhzad OC; Cheng J; Teply BA; Sherifi I; Jon S; Kantoff PW; Richie JP; Langer R
    Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6315-20. PubMed ID: 16606824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer.
    Adekiya TA; Hudson T; Bakare O; Ameyaw EE; Adebayo A; Olajubutu O; Adesina SK
    Biomed Pharmacother; 2024 Aug; 177():117125. PubMed ID: 39002444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
    Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
    J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
    Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
    J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
    Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy.
    Chu KS; Schorzman AN; Finniss MC; Bowerman CJ; Peng L; Luft JC; Madden AJ; Wang AZ; Zamboni WC; DeSimone JM
    Biomaterials; 2013 Nov; 34(33):8424-9. PubMed ID: 23899444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting the therapeutic efficacy of discoidal nanoconstructs against glioblastoma with rationally designed PEG-Docetaxel conjugates.
    Felici A; Schlich M; Di Mascolo D; Goldoni L; Lisa Palange A; Decuzzi P
    Eur J Pharm Biopharm; 2022 May; 174():90-100. PubMed ID: 35358697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.
    Liu J; Kopečková P; Pan H; Sima M; Bühler P; Wolf P; Elsässer-Beile U; Kopeček J
    Macromol Biosci; 2012 Mar; 12(3):412-22. PubMed ID: 22493797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
    Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
    Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
    [No Abstract]   [Full Text] [Related]  

  • 16. Formulation and dosage of therapeutic nanosuspension for active targeting of docetaxel (WO 2014210485A1).
    Pooja D; Kulhari H; Adams DJ; Sistla R
    Expert Opin Ther Pat; 2016 Jul; 26(7):745-9. PubMed ID: 27088623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficiency of D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer.
    Wang Z; Zeng X; Ma Y; Liu J; Tang X; Gao Y; Liu K; Zhang J; Ming P; Huang L; Mei L
    J Biomed Nanotechnol; 2014 Aug; 10(8):1509-19. PubMed ID: 25016651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo.
    Feng L; Wu H; Ma P; Mumper RJ; Benhabbour SR
    Int J Nanomedicine; 2011; 6():2545-56. PubMed ID: 22072889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
    Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
    Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.